Atsena Therapeutics
company
About
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $55M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.Atsena has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$63.15M
Atsena Therapeutics has raised a total of
$63.15M
in funding over 2 rounds. Their latest funding was raised on
Dec 16, 2020 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 16, 2020 | Series A | $55M | 1 | — | — | Detail |
| Apr 1, 2020 | Series A | $8.15M | 1 |
Foundation Fighting Blindness
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Atsena Therapeutics is funded by 2 investors.
Foundation Fighting Blindness
and Retinal Degeneration Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Foundation Fighting Blindness
|
Yes | Series A |
Retinal Degeneration Fund
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
